Evidence map›Paper›PMID 28074487›Full record

ArticleAlimentary pharmacology & therapeutics2017

Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases.

R W Winter, E Collins, B Cao, M Carrellas, A M Crowell, J R Korzenik

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Patterns of vitamin D testing and supplementation for children with inflammatory bowel disease in Australasia.JGH open : an open access journal of gastroenterology and hepatology · 2024
    Article
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

R W WinterDivision of Gastroenterology and Hepatology, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-6688-0552
E CollinsDivision of Gastroenterology and Hepatology, Brigham and Women's Hospital, Boston, MA, USA.
B CaoDivision of Gastroenterology and Hepatology, Brigham and Women's Hospital, Boston, MA, USA.
M CarrellasDivision of Gastroenterology and Hepatology, Brigham and Women's Hospital, Boston, MA, USA.
A M CrowellDivision of Gastroenterology and Hepatology, Brigham and Women's Hospital, Boston, MA, USA.
J R KorzenikDivision of Gastroenterology and Hepatology, Brigham and Women's Hospital, Boston, MA, USA.
Brigham and Women's Hospital · US

Funding

ALIMENTARY TRACT RESEARCH IN HEALTH AND DISEASET32DK007533 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BLUMBERG, RICHARD S · 1986 to 2020
$5.3M
NIDDK NIH HHS T32 DK007533
6 · The paper itself

Abstract

backgroundVitamin D has been linked to disease activity among patients with inflammatory bowel diseases (IBD). Prior investigation has also suggested that vitamin D levels may affect duration of therapy with anti-tumour necrosis factor-α (anti-TNF-α) medications among patients with IBD.

aimTo evaluate the relationship between vitamin D levels and odds of reaching remission while on an anti-TNF-α medication.

methodsA total of 521 IBD patients enrolled in the Brigham and Women's IBD Centre database were eligible for inclusion. Patients treated with anti-TNF-α therapy who had vitamin D levels drawn within 6 months prior or 2 weeks after initiation of anti-TNF-α medication and who had reported remission status at 3 months were included. A logistic regression model adjusting for age, gender, IBD diagnosis, anti-TNF-α medication (infliximab vs. adalimumab) and first or subsequent anti-TNF-α medication was used to identify the effect of vitamin D level on initial response to anti-TNF-α therapy.

resultsA total of 173 patients were included in the final analysis. On logistic regression, patients with normal vitamin D levels n = 122 at the time of anti-TNF-α medication initiation had a 2.64 increased odds of remission at 3 months compared to patients with low vitamin D levels n = 51 when controlling for age, gender, diagnosis, type of anti-TNF-α medication and first or subsequent anti-TNF-α medication (OR = 2.64, 95% CI = 1.31-5.32, P = 0.0067).

conclusionsThese findings suggest that vitamin D levels may influence initial response to anti-TNF-α medication and that low vitamin D levels may pre-dispose patients to decreased odds of remission.

Indexed as

AdalimumabAdultFemaleHumansInflammatory Bowel DiseasesInfliximabLogistic ModelsMaleMiddle AgedRetrospective StudiesTumor Necrosis Factor-alphaVitamin DYoung Adult25-hydroxyvitamin DAdalimumabInfliximabTumor Necrosis Factor-alphaVitamin D

Identifiers

PMID28074487
PMCPMC5290123
OpenAlexW2568629674

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.